The Mount Sinai group did two things rather than one. They deleted AHR from neurons, and they blocked it with drugs, and both routes produced more regrowth of damaged axonal fibers [2]. That combination is worth more than either arm alone, because each fails in a different direction. An inhibitor can act on something other than its named target; a genetic deletion can be compensated for, or can act in cells you did not mean to touch. When both converge on the same phenotype, the least strained explanation is the one on the label [11].
What the summary does not carry is arithmetic. There is no animal count, no figure for how many axons crossed a lesion, no functional score against an uninjured control, and no post-injury treatment window [12]. So "better recovery of movement and sensation" [2] is a direction, not a magnitude. A first paper owes a reader direction; whether anyone should run a trial depends on magnitude.
The mechanism is the part I find genuinely interesting, and also the part that should hold enthusiasm in check. Senior author Hongyan Zou describes AHR as "a brake that shifts neurons toward managing stress rather than rebuilding damaged connections" [9], and says that "by releasing this brake, we can push neurons into a state that favors repair" [10]. Read that as an accounting identity, not a slogan: the protein's protective proteostasis response is what keeps a stressed neuron alive [3], and the same restraint caps the new protein synthesis regrowth needs [4]. Take the brake off and a neuron may enter its worst week with less quality control. The release does not say whether survival suffered, or whether survival was even measured at the doses used [12]. That is the first number I would go looking for in the paper.
Then there is the sensor point. AHR was first characterized because it detects environmental toxins [6], and Mount Sinai's own framing is that inside neurons it links external conditions to the machinery deciding whether an axon regenerates [15]. Activity that depends on exposure is activity that depends on the vivarium: diet, bedding, microbiome. If baseline brake pressure is partly set by ligand load, effect size could be a property of how these mice were housed as much as of the biology, and the same inhibitor might read stronger or weaker elsewhere. Humans do not come with standardized exposure.
Peripheral nerve injury and spinal cord injury are grouped in one sentence of the release [2], and they are separate engineering problems. Which model carries the larger share of the reported improvement is the thing to check first, since limited regenerative capacity in adult mammals is the shared premise but not the shared difficulty [14].
The practical asset here is that several AHR inhibitors are already in clinical trials for other conditions [7]. That shortens the chemistry without touching the biology questions, and the authors are explicit that dose, timing, and effects on other cells in the injury response are all still open [8]. My view, conditional on the effect sizes holding up: what will last here is the reframing itself, regeneration gated by an active brake rather than starved of a signal, more than any single molecule. If that framing holds, the search space for the next target changes shape.
